The pioneering example of molecularly driven cancer medicine was the development and use of the kinase inhibitor imatinib for the treatment of chronic myelogenous leukemias that harbor the BCR-ABL1 balanced chromosomal translocation [169]. Here, BCR is linked to cancer.